ASH 2014: Phase I study shows that PD-1 inhibitor, nivolumab, is safe and tolerable in relapsed or refractory Hodgkin lymphoma - 101271

Spotlight
Video

ASH 2014: Phase I study shows that PD-1 inhibitor, nivolumab, is safe and tolerable in relapsed or refractory Hodgkin lymphoma

EMJ has 458 videos Subscribe Here

Loading........
Description: At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Philippe Armand (Dana-Farber Cancer Institute, Boston, MA) discusses the results of a phase I study evaluating the preliminary efficacy and safety of programmed cell death 1 (PD-1) inhibitor, nivolumab, in patients with relapsed or refractory classical Hodgkin lymphoma.
Shared By : EMJ
Posted on : 12/09/14
Added : 3 years ago
Category : Hodgkin Lymphoma